Moderna
4 articles
Industry NewsModerna / MerckBioSpace
Moderna Returns to Profit as Cancer Vaccine Heads to a Filing
- Third-quarter revenue rose about 29% to $1.3 billion on global COVID vaccine sales, and full-year growth guidance was lifted to 15–25%. Analysts questioned how much reflects 2027 deliveries shipped early.
- Intismeran, with Merck, showed a 42% lower risk of recurrence or death in melanoma alongside Keytruda; a BLA is planned by year-end with a decision expected in 2027, and a renal cancer Phase 2 is next.
- The norovirus vaccine missed its early Phase 3 bar, so no further cohort will be enrolled this season.
Profit this quarter is seasonal COVID timing; the real story is that Moderna's identity is shifting to oncology, with intismeran its first potential approval outside respiratory vaccines. Merck shares the economics, and the open question is the manufacturing and reimbursement model for a bespoke product at launch scale.
Industry NewsMerck / ModernaBioSpace
Merck and Moderna show personalized melanoma vaccine can be made for nearly every trial patient
- In the Phase 3 INTerpath-001 melanoma study (1,137 patients), intismeran autogene plus Keytruda cut recurrence or death risk by 42% (HR 0.58).
- A manufactured vaccine reached 99% of patients assigned to it; 82% of screened patients had enough tumor tissue.
- Of those, 91% received the full set of up to 34 neoantigens, and the rest still got a shot with fewer targets.
- Merck and Moderna are also testing it in kidney, lung and bladder cancer.
The efficacy number gets the headlines, but the 99% manufacturing success rate is what a payer and a competitor should study. Bespoke-per-patient products have usually died on logistics, and this one scaled across 1,137 patients. With Keytruda facing patent expiry, Merck is building a follow-on franchise on top of its own anchor drug, and Moderna gets a credible path beyond respiratory vaccines.
Industry NewsModerna / MerckBioPharma Dive
Merck and Moderna's mRNA melanoma vaccine clears the bar at ESMO, but Moderna's stock drops
- Adjuvant intismeran plus Keytruda cut the relative risk of recurrence or death versus Keytruda alone, with a similar cut in distant spread, at about two years' median follow-up.
- Side effects were broadly similar between arms apart from more fever and injection-site pain; discontinuations for adverse events were slightly higher with the vaccine.
- Moderna's shares fell sharply after the early data leak and presentation; Merck's barely moved. Studies in lung, bladder and kidney cancer continue.
The result landed at the low end of what analysts wanted, and the benefit looks smaller than the Phase 2 signal. Approval looks plausible; the harder question is how many more tumor types a personalized, patient-by-patient manufacturing model can serve. The kidney and lung readouts will say whether this is a platform or a one-indication product.
Industry NewsMerck / ModernaSTAT News
Merck and Moderna say their mRNA cancer vaccine plan still needs a lot of exploring
- At the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li discussed pairing Keytruda with personalized mRNA cancer vaccines.
- Both executives framed the first positive results as a start, with much left to work out.
- This summary rests on the article's teaser, not the full text.
Pairing a personalized vaccine with Keytruda protects Merck's franchise as PD-1 exclusivity ages, so Merck has a strategic reason beyond the science. The executives' caution about what comes next is telling: the open questions are tumor types, dosing settings and manufacturing scale. Rivals with other neoantigen approaches should read it as a bar to clear.